SavedAdd your journal

Journals / International Journal of Chemistry and Technology / 2017 / Cilt: 1 - Sayı: 1

Determination of spectrophotometric protonation constant of cholinesterase inhibitors

Yaşar Doğan DALDAL
Ebru ÇUBUK DEMİRALAY
Güleren ALSANCAK
Pages
7–13
Publication Date
2017-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The predicted and calculated pKa values were compared with literature values.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The protonation constant (pKa) of rivastigmine, galantamine and donepezil which are cholinesterase inhibitors used in cure of Alzheimer's disease in acetonitrile-water binary mixtures were determined at 25 oC in ionic strength by spectrophotometric method.
📊
Key Findings & Data:Spectra of the drugs were recorded with 1 nm resolution over the 200 to 400 nm interval.
💡
Conclusion & Impact:The predicted and calculated pKa values were compared with literature values.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cholinesterase Inhibitors · Protonation Constant · UV-VIS Spectrophotometry

Abstract

The protonation constant (pKa) of rivastigmine, galantamine and donepezil which are cholinesterase inhibitors used in cure of Alzheimer's disease in acetonitrile-water binary mixtures were determined at 25 oC in ionic strength by spectrophotometric method. Spectra of the drugs were recorded with 1 nm resolution over the 200 to 400 nm interval. Data assessment was carried out with the STAR software program to calculate molar absorbances and stability constants of the compounds studied. Aqueous protonation constant of these compounds were calculated from determined through linear relationship between the mole fraction of acetonitrile and the pKa values and the Yasuda-Shedlovsky equality. The pKa values of inhibitors at 25°C were converted to values at 37°C, without extra estimation. The predicted and calculated pKa values were compared with literature values.

🔖

Cite This Article

DALDAL, Y. D., DEMİRALAY, E. Ç., ALSANCAK, G. (2017). Determination of spectrophotometric protonation constant of cholinesterase inhibitors. International Journal of Chemistry and Technology, Cilt: 1 - Sayı: 1, 7–13. https://ajindex.com/articles/765723

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (26)

  1. Nordberg, A.; Svensson, A.L. Drug Saf. 1998, 19(6), 465-480
  2. Thompson, P.A.; Wright, D.E.; Counsell, C.E.; Zajicek, J. Int. Psychogeriatr. 2012, 24(5), 689-697
  3. Demiralay, E.C.; Alsancak, G.; Ozkan, S.A. J. Sep. Sci. 2009, 32, 2928 - 2936
  4. Yılmaz, H.; Demiralay,E.C. J. Liq. Chromatogr. Relat. Technol. 2015, 38(1), 97-103
  5. Babič, S.; Horvat, A.J.M.; Pavlović, D.; Kaštelan Macan, M. Trends Analyt. Chem. 2007, 26(11), 1043-1061
  6. Talay, A.; Demiralay, E.C.; Daldal, Y.D.; Üstün, Z.J. Mol. Liq. 2015, 208, 286-290
  7. Tam, K.Y.; Hadley, M.; Patterson, W. Talanta 1999, 49, 539-546
  8. Tam, K.Y.; Takács-Novák, K. Anal. Chim. Acta 2001, 434, 157-167
  9. Sanli, S.; Altun, Y.; Guven, G. J. Chem. Eng. Data 2014, 59, 4015-4020
  10. Daldal, Y.D.; Çakır, C.; Yılmaz, H.; Demiralay, E.C.; Özkan, S.A.; Alsancak, G. Curr. Drug. Ther. 2014, 9, 277-284
  11. Sun, N.; Avdeef, A. J. Pharm. Biomed. Anal. 2011, 56, 173-182
  12. Narasimham, L.; Dnyandeo Barhate, V. Eur. J. Chem, 2011, 2 (1), 36-46
  13. Sanli, N.; Sanli, S.; Sızır, U.; Gumustas, M., Ozkan, S.A. Chromatographia 2011, 73(11-12), 1171-1176
  14. Canbay, H.S.; Demiralay, E.C.; Alsancak, G.; Ozkan, S.A. J. Chem. Eng. Data 2011, 56(5), 2071-2076
  15. Yasuda, M. Bull. Chem. Soc. Jpn. 1959, 32, 429-432
  16. Shedlovsky, T. Electrolytes, in: B. Peasce (Ed.), Pergamon Press, New York, 1962
  17. Marvin Sketch program, Chemaxon, http://www.chemaxon.com, (accessed 2016)
  18. Rondinini, S.; Mussini, P.R.; Mussini, T. Pure Appl. Chem. 1987, 59, 1549-1560
  19. Beltran, J.L.; Codony, R.; Prat, M.D. Anal. Chim. Acta 1993, 276, 441-454
  20. Daldal, Y.D.; Demiralay, E.C.; Ozkan, S.A. J. Braz. Chem. Soc. 2016, 27(3), 493-499
  21. NLREG Version 4.0. P.H. Sherrod. http://www.sandh.com/Sherrod, (accessed 1991)
  22. Uysal, R.; Daldal, Y.D.; Üstün, Z.; Demiralay, E.C. Eurasian J. Anal. Chem. 2017, 12(1), 23-43
  23. Meloun, M.; Bordovská, S.; Galla, L. SRX Pharmacol. 2010, 2010, 1-14
  24. Hsieh, Y.H.; Yang, Y.H.; Yeh, H.H.; Lin, P.C.; Chen, S.H. Electrophoresis 2009, 30(4), 644-653
  25. Luan, F.; Ma, W.; Zhang, H.; Zhang, X.; Liu, M.; Hu, Z.; Fan, B. Pharm. Res. 2005, 22, 1454-1460
  26. Ishihama, Y.; Nakamura, M.; Miwa, T.; Kajima, T; Asakawa, N. J. Pharm. Sci. 2002, 91(4), 933-942.